Overview
myNEO Therapeutics' ImmunoEngine platform combines immunology expertise with AI-driven technologies for personalized neoantigen discovery in cancer vaccines and T-cell therapies, mRNA codon optimization, ADA risk prediction, and multi-epitope construct design. The company serves vaccine developers, biologics innovators, and pharma partners, and offers a proprietary asset library of immunotherapy targets for partnering and licensing.
Media & appearances
- WintercircusYouTubeEngineering Leadership Program | From engineer to leaderLore Van Oudenhove recently transitioned from a developer role to CTO there and applies program learnings to its processes.
Leadership & org chart
In the news
- Turning innovation into impact for patients. 🤝 Together with Odimma Therapeutics, we’re combining our AI-driven neoantigen discovery pipeline with tailor-made synthetic DNA technology for personalized treatment of cancer patients. Let's move precision oncology forward! #personalizedvaccine #neoantigendiscovery
- Moving cancer research forward, together! 💙 Last Thursday, the myNEO team took some time away from our daily work to connect, recharge and strengthen the team behind our mission. Because the best progress happens when we move forward together. #myNEO #TeammyNEO #MovingCancerResearchForward #TeamBuilding
- It's not often that the good people of SynBioBeta mention work that one of our portfolio companies has done! A very big congratulations to the myNEO Therapeutics team!!
- Did you know? #myneoacademy #education #tcellcheckpoints
- 𝐌𝐨𝐫𝐞 𝐞𝐩𝐢𝐭𝐨𝐩𝐞𝐬 𝐝𝐨 𝗻𝗼𝘁 𝐚𝐥𝐰𝐚𝐲𝐬 𝐦𝐚𝐤𝐞 𝐚 𝐛𝐞𝐭𝐭𝐞𝐫 𝐯𝐚𝐜𝐜𝐢𝐧𝐞. 𝐁𝐞𝐭𝐭𝐞𝐫 𝐜𝐨𝐧𝐬𝐭𝐫𝐮𝐜𝐭 𝐝𝐞𝐬𝐢𝐠𝐧 𝐝𝐨𝐞𝐬. Designing an optimal multi-epitope construct means balancing dozens of parameters simultaneously. That's why we built 𝗺𝘆𝗖𝗢𝗡𝗦𝗧𝗥𝗨𝗖𝗧 within an 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝘃𝗲 𝘃𝗶𝘀𝘂𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺, making complex construct optimization transparent, interpretable, and easy to explore. The platform enables: 🔹Exploration of the complete construct optimization
- Did you know? #myneoacademy #education #biologics
- This week we celebrated a small milestone: our 100th Prioritization Meeting and Sprint Planning! 🎉 A perfect excuse for a sweet treat for the team: delicious Pastéis de Nata for everyone to enjoy. 🥮 Here's to great teamwork, many productive discussions, and the next 100 sprint plannings ahead! 🚀 #Agile #SprintPlanning #Teamwork #Milestone
- 𝐓𝐡𝐞 𝐦𝐨𝐬𝐭 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐢𝐧 𝐲𝐨𝐮𝐫 𝐜𝐨𝐧𝐬𝐭𝐫𝐮𝐜𝐭 𝐦𝐢𝐠𝐡𝐭 𝐛𝐞 𝐨𝐧𝐞 𝐲𝐨𝐮 𝐧𝐞𝐯𝐞𝐫 𝐝𝐞𝐬𝐢𝐠𝐧𝐞𝐝 In multi-epitope therapeutics, success isn't determined only by which epitopes you select, but also by 𝐡𝐨𝐰 𝐲𝐨𝐮 𝐚𝐬𝐬𝐞𝐦𝐛𝐥𝐞 𝐭𝐡𝐞𝐦. When epitopes are linked into a string-of-beads construct, the proteasome doesn't process them one by one. It generates new peptides at the junctions between epitopes. These junctional epitopes can be presented on MHC molecules and compete with — or even
Alumni 1 went on to found or lead
Christophe Van HuffelBusiness Growth Adviser→Co-Founder and CSO at OncoRNA
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.